IL5 and asthma: We identified 15 studies on the use of biological agents in severe asthma in the COVID-19 era (Table 1), including a total of 98 patients with severe asthma and concomitant COVID-19 disease, who were receiving omalizumab (30 patients), mepolizumab (32), benralizumab (18), reslizumab (4) and dupilumab (4), plus 10 patients receiving unspecified IL-5 antagonists.